A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia

Key facts

Study ID

NCT00088634

Run by

Sumitomo Pharma America, Inc.

People needed

180

Starts

2004-05-01

Expected to finish

2004-12-01

Last updated by the study team

2016-04-08

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV
• The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment
• If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception

You may not qualify if…

• The patient has used an investigational drug within the past 30 days
• The patient has participated in a previous study of this compound

Where it is running

• Birmingham Psychiatry Pharmaceutical — Birmingham, Alabama, United States
• Summit Research Group — Little Rock, Arkansas, United States
• Comprehensive NeuroScience — Cerritos, California, United States
• Collaborative Neuro Science Network, Inc. — Garden Grove, California, United States
• Optimum Health Services — La Mesa, California, United States
• California Clinical Trials — San Diego, California, United States
• CNRI, LLC San Diego — San Diego, California, United States
• Pacific Clinical Research — Upland, California, United States
• Comprehensive NeuroScience, Inc — Washington D.C., District of Columbia, United States
• Segal Institute for Clinical Research — North Miami, Florida, United States
• The Segal Institute — North Miami, Florida, United States
• University of South Florida, Department of Psychiatry and Behavioral Medicine — Tampa, Florida, United States
• Atlanta Center for Medical Research — Atlanta, Georgia, United States
• Comprehensive Neuroscience, Inc. — Hoffman Estates, Illinois, United States
• Robert Lynn Horne, MD, Suite 4 — Las Vegas, Nevada, United States
• CNS Research Institute — Clementon, New Jersey, United States
• Quantum Clinical Services Group — Philadelphia, Pennsylvania, United States
• Community Clinical Research — Austin, Texas, United States
• Future Search Trials — Austin, Texas, United States
• Claghorn-Lesem Research Clinic — Bellaire, Texas, United States
• InSite Clinical Research — DeSoto, Texas, United States
• CBH Health, L.L.C - Dominion Hospital — Falls Church, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.